Current status and future trends of the global burden of MASLD

Trends in Endocrinology and Metabolism, Journal Year: 2024, Volume and Issue: 35(8), P. 697 - 707

Published: Feb. 29, 2024

Language: Английский

---

An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Hepatology International, Journal Year: 2023, Volume and Issue: 17(4), P. 773 - 791

Published: May 19, 2023

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Gut, Journal Year: 2023, Volume and Issue: unknown, P. gutjnl - 331003

Published: Oct. 31, 2023

Objective We explored clinical implications of the new definition metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing its prevalence and associated cardiovascular (CVD) risk. Design From nationwide health screening data, we identified 9 775 066 adults aged 20–79 who underwent examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) other combined aetiology (the three collectively referred to as MASLD/related (SLD)); (4) no SLD. SLD was determined fatty index ≥30. The primary outcome CVD event, defined a composite myocardial infarction, ischaemic stroke, heart failure or death. Results MASLD, MetALD 27.5%, 4.4% 1.5%, respectively. A total 8 808 494 participants without prior followed up for median 12.3 years, during which 272 863 events occurred. cumulative incidence multivariable-adjusted risk higher than those (HR 1.38 (95% CI 1.37 1.39)). Multivariable-adjusted HR CI) 1.39 (1.38 1.40) 1.28 (1.26 1.30) 1.30 1.34) compared absence any these conditions. also non-alcoholic respective condition. Conclusion Over one-third Korean have bear high

Language: Английский

---

MAFLD predicts cardiovascular disease risk better than MASLD

Liver International, Journal Year: 2024, Volume and Issue: 44(7), P. 1567 - 1574

Published: April 20, 2024

Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been proposed as an alternative for the validated definition of metabolic fatty (MAFLD). We compared abilities MAFLD MASLD to predict risk atherosclerotic cardiovascular (ASCVD). Methods Six thousand ninety six participants from 2017 2020 National Health Nutrition Examination Survey cohort who received a thorough medical health check‐up were chosen study. The associations between status coronary surrogates, such 10‐year ASCVD self‐reported events, analysed. Results identified in 2911 (47.7%) 2758 (45.2%) patients, respectively. (odds ratio [OR]: 2.14, 95% confidence interval [CI], 1.78–2.57, p < .001) was more strongly independently associated with high than (OR: 1.82, CI, 1.52–2.18, comparison absence each condition. However, MAFLD, alone not increased risk. Multiple logistic regression revealed that significantly 2.82; CI: 1.13–7.01; .03) alone. Conclusions Although both different risks, predicted better MASLD. higher predictive ability attributed dysfunction rather moderate alcohol use.

Language: Английский

---

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies

Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 76(3), P. 454 - 499

Published: Jan. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Language: Английский

---

Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(4), P. e157 - e159

Published: March 28, 2024

Language: Английский

---

Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease

Gut, Journal Year: 2024, Volume and Issue: 73(11), P. 1883 - 1892

Published: Aug. 1, 2024

Background Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). Aim To explore the effects of statins on long-term risk all-cause mortality, liver-related clinical events (LREs) and stiffness progression MASLD. Methods This cohort study collected data MASLD undergoing at least two vibration-controlled transient elastography examinations 16 tertiary referral centres. Cox regression analysis was performed to examine association between statin usage mortality LREs stratified by compensated advanced chronic (cACLD): baseline measurement (LSM) ≥10 kPa. Liver defined as an LSM increase ≥20% for cACLD from <10 kPa or non-cACLD. reduction decrease cACLD. Results We followed up 7988 5.9 (IQR 4.6–8.2) a median 4.6 years. At baseline, 40.5% used statins, present 17%. Statin significantly associated lower (adjusted HR=0.233; 95% CI 0.127 0.426) HR=0.380; 0.268 0.539). also rates (HR=0.542; 0.389 0.755) non-cACLD HR=0.450; 0.342 0.592), but not HR=0.914; 0.778 1.074). Conclusions relatively

Language: Английский

---

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

---

Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions

Liver International, Journal Year: 2023, Volume and Issue: 43(6), P. 1170 - 1182

Published: April 5, 2023

Hepatocytic ballooning is a key histological feature in the diagnosis of non-alcoholic steatohepatitis (NASH) and an essential component two most widely used scoring systems for diagnosing staging fatty liver disease (NAFLD) [namely, NAFLD activity score (NAS), steatosis, fibrosis (SAF) system]. As result increasing incidence NASH globally, diagnostic challenges hepatocytic are unprecedented. Despite clear pathological concept ballooning, there still assessing 'real life' situations. can be confused with cellular oedema microvesicular steatosis. Significant inter-observer variability does exist presence severity ballooning. In this review article, we describe underlying mechanisms associated Specifically, discuss increased endoplasmic reticulum stress unfolded protein response, as well rearrangement intermediate filament cytoskeleton, appearance Mallory-Denk bodies activation sonic Hedgehog pathway. We also use artificial intelligence detection interpretation which may provide new possibilities future treatment.

Language: Английский

---

Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study

Arteriosclerosis Thrombosis and Vascular Biology, Journal Year: 2023, Volume and Issue: 43(3), P. 482 - 491

Published: Feb. 2, 2023

In cross-sectional and retrospective cohort studies, we examined comparative associations between nonalcoholic fatty liver disease (NAFLD) metabolic dysfunction-associated (MAFLD) risk of having or developing coronary artery calcification (CAC). Participants who had health examinations 2010 2019 were analyzed. Liver ultrasonography computed tomography used to diagnose CAC. divided into a MAFLD no-MAFLD group then NAFLD no-NAFLD groups. further no (reference), NAFLD-only, MAFLD-only, both Logistic regression modeling was performed. Cox proportional hazard model examine the incident CAC in participants without at baseline least two measurements. analyses, 162 180 included. Compared with either groups, groups associated higher prevalent (NAFLD: adjusted odds ratio [OR], 1.34 [95% CI, 1.29-1.39]; MAFLD: OR, 1.44 1.39-1.48]). Among 4 MAFLD-only strongest association (adjusted 1.60 1.52-1.69]). Conversely, NAFLD-only lower 0.76 0.66-0.87]). longitudinal 34 233 ratio, 1.68 1.43-1.99]; 1.82 1.56-2.13]). these 2.03,[95% 1.62-2.55]). The not independently 0.88 0.44-1.78]) Conclusions: Both are significantly an increased prevalence incidence These tended be stronger for MAFLD.

Language: Английский

---